The comments above prompted me to look at the presentation, which I found to be informative, and helpful. I have no special love of pictures, but I do like data to be transparent, and sufficiently detailed to allow evaluation.
A few things I noted:
They have clear market strategies, have their finger on the pulse, and understand the need to rebalance their portfolio when market conditions alter.
They are largely holding their 60% market share of Doryx, in spite of new entrants to the market
Mayne are filling more dermatology prescriptions per week in total - from March 2017 to March 2019, they increased from around 5,500 to approx 7000. = growth
They have a strong development pipeline, with a number of late stage products.
They understand the incremental value of adding additional complementary products within the same categories where they currently offer products. This leverages the existing sales team, and their field of expertise
Their half yearly report clearly showed revenue growth, and a healthy underlying NPAT. The biggest drag on actual PAT appears to be depreciation, rather than margin loss.
Looks like a healthy, and relatively well functioning company to me (apart from Director remuneration). All in my own opinion.
MYX Price at posting:
67.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)